Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? IDEXX Laboratories, Inc. trades at $572.03 (market cap $46.22B), while Vanguard Total International Stock Index Fund ETF trades at $87.48. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | VXUS | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Sector/Thematic |
52-Week High | $766.68 | $87.21 |
52-Week Low | $526.44 | $70.87 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
VXUS, the Vanguard Total International Stock ETF, trades at $87.72, up 1.02% on the day, with a bullish technical signal driven by strong moving average alignment. Recent news highlights its role in global diversification, with a 27.82% total return over the past year noted by Seeking Alpha on August 8, 2026. The ETF offers exposure to over 8,700 non-U.S. stocks, attracting institutional interest, though RSI levels suggest potential near-term overbought conditions.
The outlook for VXUS is supported by its valuation discount to U.S. equities and broad diversification benefits, but risks include global economic sensitivity and inflationary pressures. Analyst sentiment is mixed, with some advocating buys for long-term portfolios while others caution on growth-inflation dynamics. Institutional holdings have increased, reflecting confidence in international market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
